CordenPharma invests €80m to expand sterile injectable capacity to 500m units annually
CordenPharma is investing €80 million to expand aseptic fill-finish operations at its Caponago site in Italy, increasing projected sterile injectable capacity to up to 500 million units annually.
The expansion will add new aseptic filling lines and strengthen CordenPharma's ability to manufacture and package sterile injectable medicines for pharmaceutical and biotechnology customers.
The investment reflects growing demand for outsourced sterile manufacturing capacity and forms part of the company's broader strategy to scale high-value injectable drug production across its global network.
Field | Content |
Alert Type | Industry Update |
Company | CordenPharma |
Development Type | Manufacturing capacity expansion |
Investment | €80 million |
Facility | Caponago manufacturing site |
Location | Italy |
Manufacturing Area | Aseptic fill-finish; sterile injectables |
Projected Capacity | Up to 500 million sterile injectable units annually |
What Happened | CordenPharma announced an €80 million investment to expand aseptic fill-finish capacity at its Caponago facility in Italy. |
Why It Matters | The expansion substantially increases sterile injectable manufacturing capacity at a time of strong demand for outsourced aseptic production services. |
Supporting Context | The programme includes additional aseptic filling infrastructure designed to support pharmaceutical and biotechnology customers across multiple injectable formats. |
Strategic Rationale | CordenPharma is scaling high-value sterile manufacturing capabilities to strengthen its position as a global contract development and manufacturing partner. |
Potential Impact | The added capacity could support greater commercial supply volumes and provide drug developers with additional European sterile manufacturing options. |
Key Takeaway | CordenPharma is investing €80 million to scale its Italian sterile injectable operations toward 500 million units of annual capacity. |
What to Watch | Completion of the new filling lines, customer onboarding and utilisation of the expanded Caponago capacity. |
Primary Source | CordenPharma |
Relevant Date | 10 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios